Search Results - "Tyburski, Karin"

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer by MATULONIS, Ursula A, BERLIN, Suzanne, LEE, Hang, LEE, Julie, ROCHE, Maria, HILL, Margaret, WHALEN, Christin, SULLIVAN, Laura, TRAN, Chau, HUMPHREYS, Benjamin D, PENSON, Richard T, IVY, Percy, TYBURSKI, Karin, KRASNER, Carolyn, ZARWAN, Corrine, BERKENBLIT, Anna, CAMPOS, Susana, HOROWITZ, Neil, CANNISTRA, Stephen A

“…Angiogenesis is important for epithelial ovarian cancer (EOC) growth, and blocking angiogenesis can lead to EOC regression. Cediranib is an oral tyrosine…”
Get full text

Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor by Robinson, Emily S, Matulonis, Ursula A, Ivy, Percy, Berlin, Suzanne T, Tyburski, Karin, Penson, Richard T, Humphreys, Benjamin D

“…Hypertension and proteinuria are common but poorly understood renal toxicities of vascular endothelial growth factor (VEGF) receptor signaling pathway…”
Get full text

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer by Liu, Joyce F, Tolaney, Sara M, Birrer, Michael, Fleming, Gini F, Buss, Mary K, Dahlberg, Suzanne E, Lee, Hang, Whalen, Christin, Tyburski, Karin, Winer, Eric, Ivy, Percy, Matulonis, Ursula A

“…Abstract Background Poly(ADP-ribose) polymerase (PARP)-inhibitors and anti-angiogenics have activity in recurrent ovarian and breast cancer; however, the…”
Get full text

A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies by Campos, Susana M., Berlin, Suzanne, Krasner, Carolyn N., Whalen, Christin, Atkinson, Tina, Meegan, Kristin, Pereira, Lauren, Tyburski, Karin, Lou, Weixiu, Lee, Hang, Horowitz, Neil, Penson, Richard T.

“…Purpose Temsirolimus, a mTOR inhibitor, and AZD2171, a VEGFR inhibitor, have independently shown activity in patients with gynecological malignancies…”
Get full text

A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma by Campos, Susana M, Penson, Richard T, Matulonis, Ursula, Horowitz, Neil S, Whalen, Christin, Pereira, Lauren, Tyburski, Karin, Roche, Maria, Szymonifka, Jackie, Berlin, Suzanne

“…Abstract Objective Ovarian cancer is a highly angiogenic tumor and a model for antiangiogenic research. The tyrosine kinase receptor inhibitors target several…”
Get full text

A Phase 1 trial of the PARP inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer by Liu, Joyce F., Tolaney, Sara M., Birrer, Michael, Fleming, Gini F., Buss, Mary K., Dahlberg, Suzanne E., Lee, Hang, Whalen, Christin, Tyburski, Karin, Winer, Eric, Ivy, Percy, Matulonis, Ursula A.

Get full text